Sheet	1	of	4
OHEEL		OI.	<u> </u>

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Serial No. Atty Docket No. 09/602,812 P1467R2

Applicant

23 Jun 2000

Adams et al. Filing Date

Group To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

xaminer nitials		Document Number	Date	Name	Class	Subclass	Filing Date
A1-	116	4,753,894	28.06.88	Frankel et al.			
	117	4,935,341	19.06.90	Bargmann et al.			
	118	4,943,533	24.07.90	Mendelsohn et al.			
	119	4,975,278	04.12.90	Senter et al.		l i	
	120	5,169,774	08.12.92	Frankel et al.			
	121	5,288,477	22.02.94	Bacus, S.			
	122	5,359,046	25.10.94	Capon et al.			
	123	5,367,060	22.11.94	Vandlen et al.		İ	
	124	5,401,638	28.03.95	Carney et al.			
	125	5,464,751	07.11.95	Greene et al.			
	126	5,578,482	26.11.96	Lippman et al.			
	127	5,604,107	18.02.97	Carney et al.			
	128	5,663,144	02.09.97	Greene et al.		ļ	
1	129	5,705,157	06.01.98	Greene, M. L.			
	130	5,720,937	24.02.98	Hudziak et al.			
	131	5,720,954	24.02.98	Hudziak et al.			
	132	5,725,856	10.03.98	Hudziak et al.			
	133	5,726,023	10.03.98	Cheever et al.			
	134	5,728,687	17.03.98	Bissery, M.			
	135	5,747,261	05.05.98	King et al.			
İ	136	5,770,195	23.06.98	Hudziak et al.			
	137	5,772,997	30.06.98	Hudziak et al.			
	138	5,776,427	07.07.98	Thorpe et al.			
	139	5,801,005	01.09.98	Cheever et al.			
	140	5,834,229	10.11.98	Vandlen et al.	_		
	141	5,837,243	17.11.98	Deo et al.			
.	142	5,837,523	17.11.98	Greene et al.	ļ		
	143	5,840,525	24.11.98	Vandlen et al.		Ì	
	144	5,846,538	08.12.98	Cheever et al.			
	145	5,856,110	05.01.99	Vandlen et al.			
	146	5,859,206	12.01.99	Vandlen et al.			
	147	5,869,445	09.02.99	Cheever et al.			
1	148	5,876,712	02.03.99	Cheever et al.			
1	149	5,877,305	02.03.99	Huston et al.			
1'/	150	5,908,835	01.06.99	Bissery, M.	1		
	151	5,910,486	08.01.99	Curiel et al.	}		1

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	2	of	4
-------	---	----	---

To Be Assigned

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. P1467R2

Serial No. 09/602,812

Applicant

Filing Date

23 Jun 2000

Applicant
Adams et al.

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

xaminer nitials	-	Document Number	Date	Name	Class	Subclass	Filing Date
121+	152	5,922,845	13.07.99	Deo et al.			
17	153	5,939,531	17.08.99	Wels et al.			
	154	5,968,511	19.10.99	Akita et al.			
	155	5,977,322	02.11.99	Marks et al.			
	156	5,985,553	16.11.99	King et al.			•
1	157	6,015,567	18.01.00	Hudziak et al.			
	158	6,028,059	22.02.00	Curiel et al.			
	159	6,054,297	25.04.00	Carter et al.			
	160	6,054,561	25.04.00	Ring			
}	161	6,096,873	01.08.00	Schaefer et al.	1	-	
-1	162	6,123,939	26.09.00	Shawver et al.			
V	163	6,165,464	26.12.00	Hudziak et al.			

FOREIGN PATENT DOCUMENTS

Examiner							Transla	ation
Initials		Document Number	Date	Country	Class	Subclass	Yes	No
IAIF	164	0,616,812 A1	28.09.94	EPO				
1	165	711,565	26.08.98	EPO			1	ĺ
\	166	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)				1
	167	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	168	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)				ļ
	169	5-117165	14:05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)	Ì	ļ		
	170	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)	ŀ			1
	171	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		l	1	
1	172	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		1		ļ
1	173	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)				
1	174	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)	-			
1	175	WO 00/61185	19.10.00	PCT	}			1
1	176	WO 89/06692	27.07.89	PCT			Ì	1
	177	WO 92/10573	25.06.92	PCT		İ		
- 1	178	WO 93/12220	24.06.93	PCT				
	179	WO 93/21232	28.10.93	PCT				ì
	180	WO 93/21319	28.10.93	PCT .			ļ	
	181	WO 94/28127	08.12.94	PCT				
	182	WO 95/16051	15.06.95	PCT	1	ļ		
	183	WO 95/17507	29.06.95	PCT				
	184	l l	26.10.95	PCT		1		1
\mathcal{U}								

Examiner / \

Date Considered

12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	3	of	4
Onco		01	

To Be Assigned

F)F	M	Pī	∩-1	449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

Applicant Adams et al.

Filing Date

23 Jun 2000

Group

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner							Translation	
nitials		Document Number	Date	Country	Class	Subclass	Yes	No
ALH	185	WO 96/18409	20.06.96	PCT				
1	186	WO 97/04801	13.02.97	PCT				
	187	WO 97/20858	12.06.97	PCT				
	188	WO 97/27848	07.08.97	PCT			!	
	189	WO 97/38731	23.10.97	PCT				
1	190	WO 98/45479	15.10.98	PCT				
1/	191	WO 99/31140	24.06.99	PCT				

		OTHER DISCLOSURES (Including Author, Title, Date, Pertine	ent Pages, etc.)
AH	192	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAb) Alone Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)	of ASCO-13th Annual Meeting
	193		
	194	Baselga et al., "Monoclonal antibodies directed against growth factor chemotherapeutic agents" Annals of Oncology (abstract #010) 5(Suppl.	5) (1994)
	195	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Hercepting of Paclitaxel and Doxorubicin against HER2/neu Overexpessing Human Branch 58:2825-2831 (July 1998)	reast Cancer Xenografts" <u>Cancer</u>
	196	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu (552:1916-1923 (1992)	
\top	197	DiFiore et al., "erbB-2 is a potent oncogene when overexpressed in N 237(4811):178-182 (Jul 10, 1987)	•
	198	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody tumor antigen" Proc. Natl. Acad. Sci. 83:9129-9133 (1986)	•
	199	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Effects In Vivo" Oncogene 2(4):387-394 (1988)	
	200	Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd editio (1981)	n, New York, NY:Wiley pps. 13-17
	201	⁻	
	202	Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Research 54(3):738-741 (Feb 1, 1994)	•
	203	Guy et al., "Expression of the neu protooncogene in the mammary epit metastatic disease" Proc. Natl. Acad. Sci. USA 89(22):10578-10582 (N	fov 15, 1992)
	204	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in ca 4 1198(2-3):165-184 (Dec 30, 1994)	
	205	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhib in vitro" <u>Proceedings of the American Association for Cancer Researce</u>	th (abstract #3209) 37:470 (Mar 199
V	206	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extr 6 c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January	acellular Domain of the Human , 1989)
Exami	ner /	Date Co	onsidered 12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4	of	4	_
Serial No.			— :
09/602,812			i

-c	PTC	١ 1	4 A O

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. P1467R2

Applicant

Adams et al.

LIST OF DISCLOSURES CITED BY APPLICANT

(U	se seve	eral sheets if necessary)	Filing Date 23 Jun 2000	Group To Be Assigned								
<u>-</u>		OTHER DISCLOSURES (Including Author, Title, Date, I	Pertinent Pages, etc.)									
ALH	207	Mendelsohn et al., "Receptor blockade and chemotherapy: a new ap Annals of Oncology (abstract #040) 7(Suppl. 1):22 (1996)	py: a new approach to combination cancer therapy"									
Norton, L, "Evolving concepts in the systemic drug therapy of breast cancer" <u>Seminars in Oncolo</u> 208 Suppl 10):S10-3-S10-10 (Aug 1997)												
	209											
		Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as F Women with Metastatic Breast Cancer Whose Tumors Overexpress HE 18:137a (1999) Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognost	R2" Proceedings of As	ker in breast								
		cancer: a paradigm for the development of other macromolecular (14, 1995) Rodeck et al., "Interactions between growth factor receptors and the control of t	markersa review" <u>Ge</u>	<u>ne</u> 159(1):19-27 (Jun								
		human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987) Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)										
	214	Seifert et al., "Dexrazoxane in the prevention of doxorubicin-i Pharmacotherapy 28(9):1063-1072 (Sep 1994)										
	215	Singal and Iliskovic, "Doxorubicin-induced cardiomyopathy" New (Sep 24, 1998)										
	216	Singal et al., "Combination therapy with probucol prevents adri Molecular & Cellular Cardiology 27(4):1055-1063 (Apr 1995)										
	217	Sliwkowski et al., "A humanized monoclonal antibody for the tre cancer" <u>Proceedings of the American Association for Cancer Rese</u>	arch 37:625-626 (Mar	1996)								
V	218	Zhang et al., "Shared antigenic epitopes and pathobiological fu antibodies" <u>Experimental and Molecular Pathology</u> 67:15-25 (1999	nctions of anti-p185	nerz/neu monocional								
			-									
		·	·									
Exami	ner	Unne L'Aillean	Date Considered 12/2	1/03								

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	1	of	1

			4./
FORM PTO-1449	3 4	UI	*
1 011111110 1770	3	172	달:
	巴	1000	S
	æ.		4
LIST OF DISCLOS	SURESPA	CITED BY	PPLICANT
	- (UEMARK O.	
(Use several sh	eets if n	ecessary)	

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. Serial No. P1467R2 09/602,812

Applicant
Adams et al.

Filing Date Group
23 Jun 2000 1642

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS									
xaminer nitials	Document Number	Date	Name	Class	Subclass	Filing Date			
Aut	224 5,804,396	08.09.98	Plowman			12.10.94			
	,								
	•								
			-						
-									
			ļ						
	,								
xaminer	annel He	llesses		Date Considered	117/2003				

Unil Holling

11/17/2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

, r - d		2 2 2002 (2)
FORM PTO-1449	PARTE	
LIST OF DISCLOSURES CITED BY	APPLIC	ANT

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. Serial No. P1467R2 09/602, 812

Applicant

Adams et al.

23 Jun 2000

Group 1642

(Use several sheets if necessary)

•

U.S. PATENT DOCUMENTS

	•			U.S. PATENT DOCUMENTS			
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
MI	225	6,417,168	09.07.02	Greene et al.		TECH CENTER 1600/2900	
Examine	r	Λ	21 10	ļ 1	Date Considered ,	2+ 21	_

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Oct 21, 2002

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. Serial No. P1467R2 09/602,812

Applicant

Adams et al. Filing Date

23 Jun 2000

Group

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner			_			_	
nitials		Document Number	Date	Name	Class	Subclass	Filing Date
MH	236	2002/0076695	20.06.02	Ross, J.			-
MH	237	2002/0155527	24.10.02	Stuart et al.			
ALL	238	5,514,554	07.05.96	Bacus, S.	Name of the last o		-
AUH	239	5,571,894	05.11.96	Wels, W. et al.		-	State of the state
M4	240	5,587,458	24.12.96	King, C. et al.			ora to the same
MH	241	5,783,404	21.07.98	Koski, R.	THE PERSON NAMED IN		And the second second
ALH	242	5,846,749	08.12.98	Slamon et al.	Kanada Ka		man ce _{in 3}
ALH	243	5,856,089	05.01.99	Wang et al.	Manage of Carte	نتھیس <i>ھیش</i> د ۔: ج سی _{دی} ں	manager to the first
AeH)	244	5,882,864	16.03.99	An et al.	August Law Service Services		೬೬ಕ್ಷ ಹ
Arth	245	5,925,519	20.07.99	Jensen et al.	the second	್ಷ ಎನ್.ಕಟ	an in the same
ALH	246	5,994,071	30.11.99	Ross et al.		on Tark	e e
AL4	247	6,270,765	07.08.01	Deo et al.	-	harmon and a second	ر خد ن
ALH	248	6,333,348	25.12.01	Vogel et al.			:
ALH	249	6,358,682	19.03.02	Jaffee et al.			
AH	250	6,395,272	28.05.02	Deo et al.	-		
ALH	251	6,403,630	11.06.02	Dannenberg et al.	****	ethanima d., L	-4x
mit	252	6,458,356	01.10.02	Arakawa et al.	b		. 4
AUH	253	6,512,097	28.01.03	Marks et al.			,

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translatio Yes	n No
ALH	254	1,006,194	07.06.00	EPO				
ALL	255	412,116	29.11.95	EPO				
Ar H	256	444,181	31.10.01	EPO	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	ALLEGE OFFICE AND A TOP OF THE PERSON NAMED IN COLUMN 1 TO THE		ne:
Alt	257	494,135	10.04.96	EPO	هافك بالأشير رييه يقو و براجهه يواه	b andere the new graph of the		
MH	258	502,812	14.08.96	EPO	Walker Co. 1 M to the TARMA (Proc.)	iaa ereariar e	· Mariana Maria	
ALIT	259	554,441	27.01.99	EPO	Strang 25ab Milania	: .ಎಕ್#ಡ . ಶಾ•	Service	
121+	260	656,367	07.06.95	EPO		Twice or other more	** ** **	
Mult	261	WO 01/05425	25.01.01	PCT	** * #			
nut	262	WO 01/09187	08.02.01	PCT	,			
Aut	263	WO 01/20033	22.03.01	PCT	•			
192H	264	WO 01/21192	29.03.01	PCT		···		
Aut	265	WO 01/32155	10.05.01	PCT				
Mith	266	WO 87/07646	17.12.87	PCT	Section of the present	ودهند میروند . مرب	emer the	
mir	267	WO 89/10412	02.11.89	PCT				
ALH	268	WO 91/02062	21.02.91	PCT	C			
Cyamina		7						

Examiner L'Arlluan

Date Considered 11 19 03

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Patent and Trademark Office

Use several sheets if necessary)

Atty Docket No.
P1467R2
O9/602,812

Applicant
Adams et al.

Filing Date
23 Jun 2000
1642

FOREIGN	PAIENI	DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translati Yes	ion No
ALH	269	WO 91/05264	18.04.91	PCT	-			
'AUH	270	WO 93/03741	04.03.93	PCT	ينده مسلم فللت في المالية			
ALIT	271	WO 93/16185	19.08.93	PCT	پوتاند درد و متصفحت میان	No. of the second	ur sa	
ALH	272	WO 96/07321	14.03.96	PCT	Caret 177			
ALH	273	WO 96/16673	06.06.96	PCT		-		
AH	274	WO 96/40789	19.12.96	PCT	·	·		
24	275	WO 97/00271	03.01.97	PCT	1			
A24	276	WO 98/02463	22.01.98	PCT	t			
A14	277	WO 98/16628	23.04.98	PCT	٠			
A214	278	WO 98/18489	07.05.98	PCT		r + p		
ALH	279	WO 98/33914	06.08.98	PCT	Marian and the].	
AH	280	WO 99/55367	04.11.99	PCT	, , , , , ,			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

1	OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)							
ALIH	281	Agus at al., "Differential Anti-Tumor Effects of Targeting Distinct Epitopes of the Her-2/neu Extracellular Domain in Xenograft Models of Prostate Cancer." Proceedings of the American Association						
		for Cancer Research Annual Meeting (Abstract #4570) 41:719 (Mar 2000)						
1 1		Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-Dependent and						
ALH	282	-Independent Human Xenograft Models" <u>Cancer Research</u> 59:4761-4764 (1999)						
A		American Cancer Society Textbook of Clinical Oncology, Murphy et al., 2nd edition, Atlanta:American						
ARH	283	Cancer Society pps. 126-127 (1995)						
		Ching, K., "Role of c-erb B gene family in prostate cancer" Dissertation Abstracts International						
PRH	284	55(11):4738-B (May 1995)						
- -		Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" Cancer Immunology and						
ALH	285	Immunotherapy 45(3-4):210-215 (Nov-Dec 1997)						
A. II	200	Curti, B., "Physical barriers to drug delivery in tumors" Critical Reviews in Oncology-Hematology 14(1):29-39 (Feb 1993)						
Aret .	286	14(1):25-35 (reb 1553)						
		Ezeh et al., "Differential activation of ErbB receptors in the rat olfactory mucosa by transforming						
AH	287	growth factor-α and epidermal growth factor in vivo" <u>Journal of Neurobiology</u> 37(2):199-210 (Nov 5, 1998)						
		Gibson et al., "A novel method for real time quantitative RT-PCR" Genome Research 6(10):995-1001 (Oct						
MH	288	1996)						
<u> </u>		Gura, T., "Systems for identifying new drugs are often faulty" Science 278(5340):1041-1042 (Nov 7, 1997)						
MH	289	bara, 1., by beening for racinety ling new arage are order racine, become 270(3340).1041 1012 (100 7, 1357)						
1101.	1							
ر ۸		Heid et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (1996)						
ALH	290							
_ , ,		Jain, R., "Barriers to drug delivery in solid tumors" Scientific American 271(1):58-65 (Jul 1994)						
Alt	291							
* *								
النها		James et al., "Phase II Trial of the Bispecific Antibody MDX-H210 (anti-Her2/Neu X anti-CD64) Combined						
ALH		With GM-CSF in Patients With Advanced Prostate and Renal Cell Carcinoma That Express Her2/Neu." <u>British</u> Journal of Cancer (Abstract #56) 78:19 (1998)						
Caramain a		Modified of Cancel (Abscract #56) 76:19 (1996)						

Examiner Date Considered 11/19/

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

_ of <u>3</u> _	
	_ of <u>3</u> _

FORM PTO-1449 U.S. Dept. of Commerce			Atty Docket No.	Serial No.	
		Patent and Trademark Office	P1467R2	09/602,812	
			Applicant		
LIST OF DISCLOSURES CITED BY APPLICANT			Adams et al.	<u> </u>	
(Use several sheets if necessary)			Filing Date	Group	
			23 Jun 2000	1642	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
ANT	293	Annu. Meet. Soc. Clin. Oncol. (Abstract No. 1681) 17:436a (1998	carcinomas that express HER2/NEU ^m Proc.		
ALH	*294	abat. <u>Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th dition, Bethesda, MD (1991)			
A14	295	Knox et al., "Yttrium-90-labeled anti-CD20 monoclonal antibody Clinical Cancer Research 2(3):457-470 (Mar 1996)			
Alt	296	Medarex, Inc., "Medarex's HER-2 product show anti-cancer effects in phase II prostate and kidney studies" (company press release) (May 19, 1998)			
MH	297	Myers et al., "Intracellular antibody mediated down-regulation of p185 ^{erbB-2} expression in malignant prostatic cells" <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> (Abstract #2334) 37:342 (1996)			
ALH	298	Nagabhushan et al., "CWR22: The First Human Prostate Cancer Xenograft with Strongly Androgen-dependent and Relapsed Strains Both in Vivo and in Soft Agar" <u>Cancer Research</u> 56:3042-3046 (1996)			
MH	299	Nagy et al., "Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy" Pathology Oncology Research 5(4):255-271 (1999)			
Art	300	Okabayashi et al., "Podofilox-induced regression of Shope papillomas may be independent of host immunity" <u>Journal of Investigative Dermatology</u> 101(6):852-857 (Dec 1993)			
A214	301	Okuda et al., "The cytostome of Trypanosoma cruzi epimastigotes is associated with the flagellar complex" Experimental Parasitology 92(4):223-231 (Aug 1999)			
All	302	Sato et al., "A Metastatic and Androgen-sensitive Human Prostate Cancer Model Using Intraprostatic Inoculation of LNCaP Cells in SCID Mice" <u>Cancer Research</u> 57:1584-1589 (1997)			
ALH		Skrepnik et al., "Recombinant Oncotoxin AR209 (anti-p185 ^{erbB-2}) Diminishes Human Prostate Carcinoma Xenografts" <u>Journal of Urology</u> 161:984-989 (1999)			
ALH	304	Stearns et al., "Workgroup 2: Human Xenograft Models of Prostate Cancer" <u>Prostate</u> 36:56-58 (1998)			
MH	305	Wainstein et al., "CWR22: Androgen-dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma" <u>Cancer Research</u> 54:6049-6052 (1994)			
				New York	
Examiner		Orne L Hollinan	ate Considered	03	
*Examine	er: Initi	tial if reference considered, whether or not citation is in conformance with MPEP or commance and not considered. Include copy of this form with next communication to	609; draw line through citat to applicant.	tion	